scholarly journals Leukocytoclastic Vasculitis in a Patient with Type 1 Cryoglobulinemia

2011 ◽  
Vol 2011 ◽  
pp. 1-3
Author(s):  
Paul Y. Liu ◽  
Pamela E. Prete ◽  
Gary Kukes
Keyword(s):  
Clinical Response ◽  
Monoclonal Gammopathy ◽  
Leukocytoclastic Vasculitis ◽  
Vascular Occlusion ◽  
Mixed Cryoglobulinemia ◽  
Response To Therapy ◽  
Essential Mixed Cryoglobulinemia ◽  
Cutaneous Manifestations ◽  
Underlying Malignancy

Cutaneous manifestations of type 1 cryoglobulinemia are usually related to vascular occlusion by noninflammatory thrombosis; rarely is leukocytoclastic vasculitis seen in type 1 cryoglobulinemia. We report the case of a 64-year-old male who presented with isolated cutaneous leukocytoclastic vasculitis that was initially attributed to essential mixed cryoglobulinemia after thorough diagnostic evaluation. A lack of adequate clinical response to therapy prompted further investigation, including cryoprecipitate electrophoresis and immunofixation, which revealed an IgM kappa monoclonal gammopathy consistent with type 1 cryoglobulinemia. A renewed search for an underlying malignancy led to the discovery of early Waldenstrom's macroglobulinemia. Although leukocytoclastic vasculitis is more characteristic of mixed cryoglobulinemia, it can be a presenting manifestation of type 1 cryoglobulinemia.

scholarly journals Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia

2003 ◽  
Vol 10 (1) ◽  
pp. 70-77 ◽  
Author(s):  
Carolina Scagnolari ◽  
Milvia Casato ◽  
Francesca Bellomi ◽  
Francesca De Pisa ◽  
Ombretta Turriziani ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Clinical Response ◽  
Neutralizing Antibodies ◽  
Mononuclear Cells ◽  
Mixed Cryoglobulinemia ◽  
Mrna Levels ◽  
Type Ii ◽  
Essential Mixed Cryoglobulinemia ◽  
Peripheral Blood Mononuclear ◽  
Severe Type

ABSTRACT The efficacy of alpha interferon (IFN-α) in the treatment of severe type II essential mixed cryoglobulinemia (EMC) has been reported previously. In some patients, the development of neutralizing antibodies to recombinant IFN-α (rIFN-α) can affect the clinical response achieved with rIFN-α; a second treatment with natural IFN-α preparations may reinduce the clinical response. In the present study the ability of leukocyte IFN (LeIFN) to restore the response was investigated from a pharmacodynamic viewpoint. Specifically, the pharmacodynamic profiles of different IFN-α preparations were studied by measuring the serum neopterin levels and the levels of expression of protein MxA mRNA in in vivo peripheral blood mononuclear cells in two patients with EMC whose resistance to rIFN-α2a treatment increased concomitantly with the development of neutralizing antibodies. These markers were measured before injection and at 24 and 48 h after a single injection of rIFN-α2a, consensus IFN [(C)IFN], or LeIFN. No increase or only a slight increase in MxA mRNA levels was detectable after administration of rIFN-α2a or (C)IFN, whereas a significant increase (≥10-fold) in MxA mRNA expression was recorded following administration of LeIFN. The neutralizing antibodies to rIFN-α2a cross-react with (C)IFN. Sera from these patients neutralized most but not all of the subtypes present in the natural IFN-α (LeIFN) mixture, and no significant increase in neopterin levels was observed after these patients were switched to LeIFN treatment. In summary, the data demonstrate that the problem of neutralizing antibodies still exists and that LeIFN may induce an increase in the level of MxA mRNA expression but not an increase in neopterin levels in patients who are resistant to treatment with rIFN-α2a or (C)IFN.

Annular leukocytoclastic vasculitis associated with essential mixed cryoglobulinemia

2016 ◽  
Vol 26 (2) ◽  
pp. 186-187
Author(s):  
Yasushi Matsuzaki ◽  
Kayo Jin ◽  
Akiko Rokunohe ◽  
Satoko Minakawa ◽  
Hajime Nakano ◽  
...  
Keyword(s):  
Leukocytoclastic Vasculitis ◽  
Mixed Cryoglobulinemia ◽  
Essential Mixed Cryoglobulinemia

Essential Mixed Cryoglobulinemia Possibly Due to Hepatitis Virus

1982 ◽  
Vol 75 (11) ◽  
pp. 1411-1413
Author(s):  
PREM KUMAR ◽  
PAUL CHAKOLA ◽  
ERNESTO HOFFMANN ◽  
STEPHEN LEECH
Keyword(s):  
Hepatitis Virus ◽  
Mixed Cryoglobulinemia ◽  
Essential Mixed Cryoglobulinemia

scholarly journals Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy

2005 ◽  
Vol 52 (9) ◽  
pp. 2917-2925 ◽  
Author(s):  
David Saadoun ◽  
Ivan Bieche ◽  
Thierry Maisonobe ◽  
Tarik Asselah ◽  
Ingrid Laurendeau ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Mixed Cryoglobulinemia

scholarly journals Longitudinal high-dimensional analysis identifies biomarkers of response to anti-PD-1 immunotherapy

2021 ◽  
Author(s):  
Run-Ze Li ◽  
Xing-Xing Fan ◽  
Ze-Bo Jiang ◽  
Jumin Huang ◽  
Hu-Dan Pan ◽  
...  
Keyword(s):  
Clinical Response ◽  
Mononuclear Cells ◽  
Cell Function ◽  
Immune Cell ◽  
Response To Therapy ◽  
High Dimensional ◽  
Meso Scale Discovery ◽  
Peripheral Blood Mononuclear ◽  
Poor Outcomes ◽  
Nsclc Patients

Abstract The response to immunotherapy could be better predicted by using a wide set of biomarkers, including serum tumor markers; however, robust immune markers associated with efficacy have yet to be validated. In this study, changes in immune cell subsets from NSCLC patients treated with anti-PD1 therapy were longitudinally monitored by high-dimensional cytometry by time of flight (CyTOF) and Meso Scale Discovery (MSD) multi-cytokines kits. The frequencies of circulating CD8+ and CD8+CD101hiTIM3+ (CCT T) subsets were significantly correlated with clinical response and survival. Enrichment of these populations in peripheral blood mononuclear cells (PBMCs) indicated a poor clinical response to ICB therapy. Cell function assays revealed that these subsets were remarkably impaired, which supported the poor outcomes observed. Additionally, longitudinal analysis showed that KLRG1 expression and cytokines were associated with the response to therapy. Overall, our results provide novel potential biomarkers for guiding the management of NSCLC patients eligible to anti-PD-1 therapy, and contribute insights for new therapeutic strategies.

Sign in / Sign up

Export Citation Format

Share Document